Last reviewed · How we verify
Reyataz + Epzicom
This combination inhibits HIV reverse transcriptase and protease to block viral replication.
This combination inhibits HIV reverse transcriptase and protease to block viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Reyataz + Epzicom |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Reyataz (atazanavir) is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Epzicom (abacavir/lamivudine) is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit reverse transcriptase, blocking conversion of viral RNA to DNA. Together, they target two critical steps in the HIV replication cycle.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Hyperbilirubinemia
- Nausea
- Jaundice
- Headache
- Diarrhea
- Abacavir hypersensitivity reaction
- Rash
Key clinical trials
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (PHASE3)
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
- Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults (PHASE3)
- Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients (PHASE3)
- Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (PHASE4)
- Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reyataz + Epzicom CI brief — competitive landscape report
- Reyataz + Epzicom updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI